

30 August 2022

HEALIUS LIMITED
ACN 064 530 516
REGISTERED OFFICE:
LEVEL 6
203 PACIFIC HIGHWAY
ST LEONARDS NSW 2065
TEL: +61 2 9432 9400
FAX: +61 2 9432 9447

C₂N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia

Healius Limited (Healius) (ASX: HLS) and C₂N Diagnostics, a leader in advanced brain health diagnostics, today announced a partnership that will aim to bring C₂N's PrecivityAD™ blood test and related brain health biomarkers to the forefront of memory and dementia care in Australia. The partnership represents C₂N's first international country-wide agreement as it expands its offerings beyond the United States and Europe.

The partnership prioritises the development of widely accessible and high-quality blood testing services to help patients in Australia who are experiencing memory or thinking concerns to receive a timely and accurate diagnosis of their cognitive impairment. Under the initial phase of the collaboration, Healius will leverage its professional staff and expansive network of ~2,000 patient collection centres across Australia to collect patient samples. The samples will be analysed at C₂N's state-of-the-art CLIA-certified, CAP-accredited and ISO13485 certified lab in Missouri USA.

Early diagnosis is the first step toward determining the appropriate care plan for people undergoing an evaluation for Alzheimer's disease or other form of dementia. In Australia, the government estimates that nearly half a million people are currently living with dementia, a number that is expected to double in the next four decades.

Dr. Malcolm Parmenter, Managing Director and Chief Executive Officer of Healius adds, "Our team of pathologists and scientists is very impressed with the quality and innovation of C₂N Diagnostics. Currently, diagnostic approaches in Australia are relatively invasive and expensive. This partnership will make a real difference to the many Australians affected by cognitive impairment. New diagnostic approaches such as C₂N's PrecivityAD™ blood test will help realise the goal of early diagnosis of Alzheimer's disease at a time when optimal long-term plans and indeed preventive treatment may be possible to implement. Alzheimer's disease transcends national borders, and this international partnership is a major step forward for all of us."

Dr. Joel Braunstein, C₂N's CEO, says, "We are honoured to partner with Healius, which provides Australians with affordable, accessible, and comprehensive health care. We have learned many lessons from our PrecivityAD™ blood test experience in the United States, and we look forward to sharing these details with our colleagues at Healius. Together, we want to educate, raise quality of care, and offer clinically effective solutions for patients and care givers dealing with the concern of Alzheimer's disease. Australia's health sector is known for its innovation, and we are delighted to contribute to that legacy."

Representatives from both companies expect to release further announcements in the near future about their service offerings and how clinicians will be able to access these services to benefit patients and their families.

ENDS

For further information contact:

Janet Payne
Group Executive, Corporate Affairs
Mobile: +61 409 995 517

Charlene Jaw
Manager, Corporate Affairs
Mobile: +61 403 222 810

For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two core diagnostics businesses, pathology and imaging. Through its unique footprint of centres and its 11,000 employees, Healius provides Australia-wide specialty diagnostic services to consumers and their referring practitioners. Healius is currently exploring opportunities to sell its day hospitals business.

About C₂N Diagnostics, LLC

C₂N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C₂N strives to provide exceptional laboratory services and products in the field of brain health. C₂N's biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximising the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.